公开(公告)号：US12077784B2

公开(公告)日：2024-09-03

申请号：US18168396

申请日：2023-02-13

Applicant: Life Technologies Corporation

Inventor： Xin Yu ,  Xavier de Mollerat du Jeu ,  Chao Yan Lin ,  Jian Liu ,  Jonathan Zmuda

IPC: C12N1/06 ,  C12N1/22 ,  C12N7/00 ,  C12N15/10 ,  C12N15/86

CPC classification number: C12N7/00 ,  C12N1/06 ,  C12N15/86 ,  C12N2750/14041 ,  C12N2750/14152

Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.

公开(公告)号：US11414675B2

公开(公告)日：2022-08-16

申请号：US15721105

申请日：2017-09-29

Applicant: Life Technologies Corporation

Inventor： Xin Yu ,  Xavier de Mollerat du Jeu

IPC: C12N15/86 ,  C12N7/00

Abstract: A lentiviral vector production system comprises (a) a lentiviral culture supplement to control cell growth, (b) a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, (c) a lentiviral production enhancer comprising sodium propionate, sodium butyrate, and caffeine to boost lentiviral production, wherein the lentiviral vector production system is serum-free. A method of lentiviral vector production comprises using the lentiviral production system. Another method for lentiviral vector production comprises (a) culturing eukaryotic cells in a serum-free medium, (b) providing a lentiviral culture supplement to control cell growth, (c) transfecting the cells with a lentiviral vector using a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, and (d) providing a lentiviral production using a lentiviral production enhancer comprising sodium propionate, sodium butyrate capable of boosting lentiviral production.

公开(公告)号：US11608491B2

公开(公告)日：2023-03-21

申请号：US16798193

申请日：2020-02-21

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Xin Yu ,  Xavier de Mollerat du Jeu ,  Chao Yan Liu ,  Jian Liu ,  Jonathan Zmuda

IPC: C12N15/86 ,  C12N5/10 ,  C12N7/00 ,  C07K14/005 ,  C12N15/64 ,  C12N1/06

Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.

公开(公告)号：US10829787B2

公开(公告)日：2020-11-10

申请号：US15294586

申请日：2016-10-14

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Xin Yu ,  Xiquan Liang ,  Xavier de Mollerat du Jeu ,  Robert Jason Potter

IPC: C12N15/90 ,  C12N9/22 ,  C12N15/88 ,  A61K48/00

Abstract: Provided herein are compositions and methods useful, inter alia, for the delivery of ribonucleoprotein complexes (e.g., Cas9/guide RNA complexes) into cells. The compositions and methods provided herein are particularly useful for the delivery of ribonucleoprotein complexes into pluripotent cells and lymphatic cells.